Factors associated with vancomycin nephrotoxicity in the critically ill

Anaesthesia and Intensive Care

Volumn 43, Issue 5, 2015, Pages 594-599

  Hanrahan, T P ^a   Kotapati, C ^b   Roberts, M J ^b   Rowland, J ^b   Lipman, J ^a   Roberts, J A ^a   Udy, A ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Acute kidney injury; Glycopeptide; Infection; Intensive care unit; Sepsis; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; APACHE; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRESCRIPTION; PREVALENCE; RENAL REPLACEMENT THERAPY; CHEMICALLY INDUCED; CRITICAL ILLNESS; MIDDLE AGED; STATISTICAL MODEL;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; CRITICAL ILLNESS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; VANCOMYCIN;

EID: 84941085607     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1504300507     Document Type: Article

References (28)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-e55.
2. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734-744.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-327.
4. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
5. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37:95-101.
6. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123:1143-1149.
7. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-1336.
8. Dennen P, Douglas IS, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med 2010; 38:261-275.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829.
10. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-514.
11. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
12. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
13. Pickering JW, Endre ZH. Back-calculating baseline creatinine with MDRD misclassifies acute kidney injury in the intensive care unit. Clin J Am Soc Nephrol 2010; 5:1165-1173.
14. Moore EM, Bellomo R, Nichol AD. The meaning of acute kidney injury and its relevance to intensive care and anaesthesia. Anaesth Intensive Care 2012; 40:929-948.
15. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144.
16. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679-687.
17. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23:138-141.
18. Ronco C Kellum JA, Bellomo R, House AA. Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008; 3:531-544.
19. del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33:279-285.
20. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002; 6:313-316.
21. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11:257-282.
22. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillinresistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-1115.
23. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycinassociated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010; 123:182.e1-7.
24. Palmieri T, Lavrentieva A, Greenhalgh DG. Acute kidney injury in critically ill burn patients. Risk factors, progression and impact on mortality. Burns 2010; 36:205-211.
25. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN-time for reappraisal. Crit Care 2009; 13:211.
26. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49:1-16.
27. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7:539-543.
28. Li J, Udy AA, Kirkpatrick CMJ, Lipman J, Roberts JA. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents 2012; 39:69-72.